Best of ASCO - 2014 Annual Meeting

 

Welcome

Adjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.

Takeo Fujii

542

A prognostic nomogram to predict the benet of adjuvant radiotherapy for resected inammatory breast cancer patients.

Yang Jun Ping

e12007

A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.

Jiani Wang

528

Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.

Xiao Xu

531

ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.

Wendy Y. Chen

TPS599

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.

Nadia Harbeck

TPS596

Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.

Darran O'Connor

535

Adherence to adjuvant endocrine therapy after breast cancer in Sweden 2008-2010: A nationwide survey.

Anne Andersson

523

Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC).

Tessa Gerjanne Steenbruggen

536

Adjuvant endocrine monotherapy (ET) versus adjuvant breast radiation (RT) alone in healthy older women with stage I, estrogen receptor-positive (ER+) breast cancer: An analysis of the National Cancer Database (NCDB).

Anthony H. Bui

519

Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC.

Tiffany A. Traina

546

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.

Heather L. McArthur

TPS598

Are elderly breast cancer patients offered appropriate therapy i.e. surgery, chemotherapy, radiation, and endocrine therapy, in a rural population?

Alexander Johnson

e12053

Assessing adherence to hormone therapy (HT) in breast cancer (BC) patients receiving care at BC unit in a Uruguayan university of Hospital de Clínicas.

Cecilia Castillo

e12026

Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.

Romualdo Barroso-Sousa

517

Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

Lucia Del Mastro

504

Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population.

Alexander Johnson

e12048

BRCA1 tumor expression and clinical outcome in Uruguayan breast cancer patients diagnosed before the age of 40 years.

Silvina Malvasio

e12028

Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study.

Ivana Sestak

534

Breast cancer-specific survival outcomes among patients based on 21-gene recurrence score.

Wade T. Swenson

537

Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.

Hans-Christian Kolberg

557

Cardioprotection in patients with cancer undergoing chemotherapy: A network meta-analysis.

Pragnan Kancharla

e12008

Chemotherapy-associated lipid changes in breast cancer patients: A retrospective analysis from a high-volume institution in China.

Tao He

e12039

Chemotherapy-related outcomes in triple-negative breast cancer.

Rebecca M. Wellmann

e12049

Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.

Jose Pablo Leone

538

Clinical practice patterns on the use of adjuvant bisphosphonate for early breast cancer: A Canadian perspective.

Lara Zibdawi

e12002

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.

Juliet Richman

514

Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node-positive (N+) breast cancer patients with one to three positive nodes (N1).

Dennis Sgroi

555

Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.

Douglas W. Blayney

e12030

Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC).

Frankie Ann Holmes

e12037

Decisions on adjuvant chemotherapy for patients with breast cancer based on clinical and evolving Oncotype DX criteria.

Jamal Zekri

e12009

De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.

Hadar Goldvaser

524

Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.

Arlindo R. Ferreira

512

Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients.

Bo Chen

543

Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.

Paul Stewart

522

Does the time to initiate adjuvant chemotherapy effect outcome in patients with breast cancer? A National Cancer Database-based retrospective analysis.

Prashanth Ashok Kumar

e12054

Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+ breast cancer.

Pridvi Kandagatla

e12006

Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.

Carlos Hernando Barcenas

548

Effect of tart cherry on aromatase inhibitor-induced arthralgia (AIA) in nonmetastatic hormone-positive breast cancer patients: A randomized double-blind placebo-controlled trial.

Mina Shenouda

525

Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).

Jessica Scott

541

Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.

Lee S. Schwartzberg

539

EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity.

Lauren A Marcath

532

Evaluation of androgen receptor expression in core needle biopsies and clinico-pathological factors in primary breast cancer.

Nobuyuki Arima

e12023

Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.

Luca Gianni

515

Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.

Darya Kizub

552

Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.

Jose Pablo Leone

540

Four versus six cycles of docetaxel and cyclophosphamide in early breast cancer.

Aparna Basu

e12047

Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H).

Adrienne Gropper Waks

554

Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics.

Neelima Vidula

558

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

Otto Metzger Filho

502

Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.

Jessica Campf

556

Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.

Otto Metzger Filho

510

Impact of chemotherapy sequence on the efficacy of scalp cooling devices for alopecia prevention.

Omar Peña-Curiel

e12034

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

Joseph A. Sparano

503

Impact of delaying initiation of adjuvant chemotherapy and trastuzumab in patients with early-stage HER2-positive breast cancer.

Georgeta Fried

e12033

Impact of the extent of resection on primary breast angiosarcoma survival.

Timur Mitin

521

Impact of treatment on patient-reported pain and fatigue in early breast cancer patients receiving adjuvant radiotherapy.

Bo Angela Wan

e12019

Influence of competing risks on estimates of recurrence risk and breast cancer-specific mortality in analyses of the Early Breast Cancer Trialists Collaborative Group.

Ramy Saleh

533

Intraoperative radiotherapy in early-stage breast cancer: Multidiciplinary management and analysis of outcome.

Elizabeth Min Hui Kim

e12036

Is it possible to predict the prognostic values of Oncotype Dx using the results of web-based mathematical prognostic value models?

Tsuguo Iwatani

e12058

Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.

Luca Gianni

527

Modeling longer-term efficacy of neratinib in the extended adjuvant setting for early-stage breast cancer.

Mark D. Danese

e12011

Modeling the consequences of recurrences after trastuzumab treatment of HER2+ early-stage breast cancer.

Quan V. Doan

e12032

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

Dennis J. Slamon

TPS597

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.

Sara A. Hurvitz

500

Oncotype DX DCIS use and clinical utility: A SEER population-based study.

Yao Yuan

e12046

Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis.

Ayman Qasrawi

e12044

Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.

Katya Losk

549

Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE).

Brittney Shulman Zimmerman

e12016

PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

Pier Franco Conte

544

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Andreas Schneeweiss

513

Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database.

Zeina A. Nahleh

547

Performance of Oncotype Dx test in patients with T1bN0, grade 1, hormone receptor-positive, HER2-negative breast cancer.

Vinay K. Gudena

e12043

Pharmacokinetic (PK) characterization of irinotecan liposome injection in patients (pts) with metastatic breast cancer (mBC).

Carey K. Anders

e12003

Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and immunosuppressive effects.

Douglas W. Blayney

e12017

Prediction of neoadjuvant chemotherapeutic efficacy by CTC and cfDNA in patients with locally advanced breast cancer.

Ge Ma

551

Predictors of adjuvant chemotherapy for breast cancer patients with an intermediate Oncotype-DX score: A SEER-based population study.

Sowmya Goranta

e12014

Prognostic value of a new clinical-genomic model to predict 10-year risk of recurrence in patients with operable breast cancer.

Lei Lei

530

Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast cancer.

Ioannis Zerdes

550

Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B.

Koji Matsumoto

e12022

Role of adjuvant chemotherapy in small (≤5 mm) node-negative and hormone receptor-negative breast cancer.

Samip R. Master

e12021

Sequential versus concurrent use of chemotherapy and endocrine therapy in the adjuvant treatment of ER-positive breast cancer: A systematic review and Bayesian network meta-analysis.

Tianfu Li

e12040

Short versus long duration of adjuvant trastuzumab (T) in HER2+ breast cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).

Qurat Ul Ain Riaz Sipra

e12057

Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.

Jinani Jayasekera

526

Six cycles of adjuvant anthracycline-taxane-based chemotherapy compared with eight cycles for women with breast cancer.

Michael Lee

e12045

Stratification of oncotype (ODX) Recurrence Score (RS) by Breast Cancer Index (BCI) and its relation to discordance.

Krystal Pauline Cascetta

e12025

Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.

Sagar D. Sardesai

e12050

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

Theodoros Foukakis

553

The CYP2C19 rs4917623 single nucleotide polymorphism to predict tamoxifen efficacy in estrogen receptor-positive breast cancer patients.

Nobuyasu Yoshimoto

e12001

The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.

Isabel Pimentel

529

The effects of mindfulness meditation and progressive muscle relaxation on fatigue and quality of life in breast cancer patients receiving adjuvant paclitaxel: A three-arm randomized trial.

Zehra Gok Metin

e12051

The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting.

Debu Tripathy

e12035

The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.

Sara Bravaccini

545

The prognostic role of the androgen receptor in patients with triple-negative early breast cancers and primary surgery.

Lynn Jongen

e12042

Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.

John Bartlett

505

Treatment and prognosis analysis of elderly patients with nonmetastatic triple-negative breast cancer.

Meng Xiu

e12038

tRNA-derived small RNA fragments (tRFs) as potential biomarkers for doxorubicin resistance in breast cancer.

Xiaowei Wu

e12000

Use of ovarian suppression with endocrine therapy among premenopausal United States women with breast cancer, 2001-2016.

Sophie Emma Mayer

e12010

Use of treatment pathways reduce cost and decrease ED utilization and unplanned hospital admissions in patients (pts) with stage II breast cancer.

James L. Weese

e12012

Using tumor genomic profile testing and comorbidity level to personalize chemotherapy decisions among older patients with early-stage breast cancer.

Young Chandler

e12055

Validation of a panel of risk factors for predicting breast cancer reappearance.

Giovanni Corso

e12004

Variations in compliance with different endocrine therapies in ER-positive breast cancer in elderly females in a rural population.

Christian Agbisit

e12052

Vitamin D insufficiency and risk of paclitaxel-induced peripheral neuropathy.

Theodore Salvatore Jennaro

e12027

Weight change after (neo)adjuvant chemotherapy in a cohort of breast cancer survivors: Trends by race, hormone positivity, and chemotherapy regimen.

Bradley S Colton

e12018